Episode
Episode 74. Myeloma Updates from ASCO/EHA 2026 with Dr. Prashant Kapoor
- Podcast
- Blood Cancer Talks
- Published
- Sep 3, 2026
- Duration seconds
- 3463
- Processing state
not_requested- Canonical source
- https://share.transistor.fm/s/f4316841
Actions
POST https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-74-myeloma-updates-from-asco-eha-2026-with-dr-prashant-kapoor/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-74-myeloma-updates-from-asco-eha-2026-with-dr-prashant-kapoor.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Blood Cancer Talks — Show Notes Episode: Best of ASCO/EHA 2026 — Multiple Myeloma & AL Amyloidosis Guest: Dr. Prashant Kapoor, MD Professor of Medicine, Mayo Clinic, Rochester, MN Chair, Myeloma, Amyloidosis and Dysproteinemia Group, Mayo Clinic Episode Overview In this episode, the hosts sit down with Dr. Prashant Kapoor to review the highest-impact multiple myeloma and AL amyloidosis data from the 2026 ASCO and EHA annual meetings. The discussion centers on the rapidly shifting relapsed/refractory myeloma landscape, where a wave of phase 3 trials of T-cell engaging immunotherapies (bispecific antibodies and CAR T) have now each demonstrated superiority over traditional triplet regimens. Topics Covered 1. MajesTEC-3 Phase 3, open-label trial of teclistamab + daratumumab SC (n=291) vs. investigator's choice of DPd or DVd (n=296) in 587 patients with relapsed/refractory myeloma and 1–3 prior lines; prior BCMA-directed therapy and anti-CD38-refractory disease were exclusions (only 5% CD38-exposed, none were refractory). Initially presented at ASH 2025, with cytogenetic subgroup data updated at EHA 2026. Key results (34.5-month median follow-up): Median PFS not reached with Tec-Dara vs. 18.1 months with DPd/DVd; 36-month PFS 83.4% vs. 29.7% (HR 0.17) 36-month OS 83.3% vs. 65.0% (HR 0.46) Severe infection rate front-loaded: ~35% → ~17% between the first and second 6-month windows, plateauing at ~10–11%/window beyond 12 months; overall grade 3–4 infection 54%, 4.6% fatal infections (mostly without IVIG prophylaxis) EHA 2026 cytogenetic subgroup: 2-year PFS 90% (0 HRCA), 82% (1 HRCA), 76% (≥2 HRCA) — vs. only 14% with DPd/DVd in patients with ≥2 HRCA Discussion points: Applicability to patients at 1st/2nd relapse seen in clinic today; whether infection risk limits use of…